Compare CLDI & NXGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDI | NXGL |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 2.0M |
| IPO Year | 2021 | 2019 |
| Metric | CLDI | NXGL |
|---|---|---|
| Price | $0.65 | $3.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.3K | ★ 595.0K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.00 |
| EPS | N/A | ★ N/A |
| Revenue | $45,000.00 | ★ $11,421,000.00 |
| Revenue This Year | N/A | $38.23 |
| Revenue Next Year | N/A | $53.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.46 |
| 52 Week Low | $0.09 | $0.15 |
| 52 Week High | $3.38 | $214.40 |
| Indicator | CLDI | NXGL |
|---|---|---|
| Relative Strength Index (RSI) | 26.99 | 41.19 |
| Support Level | $0.62 | $3.12 |
| Resistance Level | $1.29 | $7.25 |
| Average True Range (ATR) | 0.07 | 0.92 |
| MACD | -0.01 | 0.32 |
| Stochastic Oscillator | 14.15 | 15.75 |
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.